US21833P3010
© Globe Newswire
11.12.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
News Preview
NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("C...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
News Preview
Company will host conference call and live webcast to review and discuss the data at 8:00 am ET Company will host conference call and live webcast to review and discuss the data at 8:00 am ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
31.10.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Announces Pricing of Public Offering
News Preview
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares of its common stock at a public offering price of $13.00 per share, and, in lieu of common stock to...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
30.10.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Announces Proposed Public Offering
News Preview
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
News Preview
NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poster at the 2025 European Society for Medical Oncology (ESMO25) Congress being held in Berlin, Germany. The poster t...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
News Preview
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701 KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
CRBP
LISTED
NASDAQ
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
News Preview
NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and nec...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
News Preview
NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Wester...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
News Preview
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
News Preview
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
News Preview
NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.03.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
News Preview
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.03.2025
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
News Preview
NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
News Preview
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
CRBP
LISTED
NASDAQ
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
News Preview
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
News Preview
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be hel...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
CRBP
LISTED
NASDAQ
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
News Preview
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalat...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2024
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
News Preview
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.08.2024
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
News Preview
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.06.2024
CRBP
LISTED
NASDAQ
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
News Preview
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate, has been presented at American Society o...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.05.2024
CRBP
LISTED
NASDAQ
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
News Preview
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
News Preview
NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
